{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05051436",
            "orgStudyIdInfo": {
                "id": "55665"
            },
            "secondaryIdInfos": [
                {
                    "id": "R01DK128033",
                    "type": "NIH",
                    "link": "https://reporter.nih.gov/quickSearch/R01DK128033"
                }
            ],
            "organization": {
                "fullName": "University of Kentucky",
                "class": "OTHER"
            },
            "briefTitle": "The Effects of Mirabegron and Tadalafil on Glucose Tolerance in Prediabetics",
            "officialTitle": "The Effects of Mirabegron and Tadalafil on Glucose Tolerance in Prediabetics",
            "therapeuticArea": [
                "Endocrinology"
            ],
            "study": "the-effects-of-mirabegron-and-tadalafil-on-glucose-tolerance-in-prediabetics"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-10",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2021-12-13",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-12-31",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-02-28",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2021-09-10",
            "studyFirstSubmitQcDate": "2021-09-10",
            "studyFirstPostDateStruct": {
                "date": "2021-09-21",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-10-26",
            "lastUpdatePostDateStruct": {
                "date": "2023-10-30",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR_INVESTIGATOR",
                "investigatorFullName": "Philip Kern",
                "investigatorTitle": "Professor",
                "investigatorAffiliation": "University of Kentucky"
            },
            "leadSponsor": {
                "name": "Philip Kern",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",
                    "class": "NIH"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": false
        },
        "descriptionModule": {
            "briefSummary": "The investigator hypothesizes that treatment with the \u00df3 agonist mirabegron results in improved glucose metabolism, including a reversal of prediabetes in obese, insulin-resistant human research participants, and this is further improved by combination therapy with tadalafil. The investigator will comprehensively analyze glucose homeostasis in prediabetic patients treated for 14 weeks with mirabegron, tadalafil or both drugs as compared to a placebo."
        },
        "conditionsModule": {
            "conditions": [
                "Pre-diabetes",
                "Obesity"
            ],
            "keywords": [
                "Tadalafil",
                "Mirabegron"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE4"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 96,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Mirabegron (M)",
                    "type": "EXPERIMENTAL",
                    "description": "Drug will be administered for 12 weeks after baseline procedures.",
                    "interventionNames": [
                        "Drug: Mirabegron 50 MG"
                    ]
                },
                {
                    "label": "Tadalafil (T)",
                    "type": "EXPERIMENTAL",
                    "description": "Drug will be administered for 12 weeks after baseline procedures.",
                    "interventionNames": [
                        "Drug: Tadalafil 10 MG"
                    ]
                },
                {
                    "label": "Mirabegron and Tadalafil (MT)",
                    "type": "EXPERIMENTAL",
                    "description": "Both drugs will be administered for 12 weeks after baseline procedures.",
                    "interventionNames": [
                        "Drug: Mirabegron 50 MG",
                        "Drug: Tadalafil 10 MG"
                    ]
                },
                {
                    "label": "Placebo (P)",
                    "type": "PLACEBO_COMPARATOR",
                    "interventionNames": [
                        "Drug: Placebo"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Mirabegron 50 MG",
                    "description": "Mirabegron 50 mg/day will be administered for 14 weeks.",
                    "armGroupLabels": [
                        "Mirabegron (M)",
                        "Mirabegron and Tadalafil (MT)"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Tadalafil 10 MG",
                    "description": "Tadalafil 10 mg/day will be administered for 14 weeks after baseline procedures.",
                    "armGroupLabels": [
                        "Mirabegron and Tadalafil (MT)",
                        "Tadalafil (T)"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Placebo",
                    "description": "Placebo will be administered for 14 weeks after baseline procedures.",
                    "armGroupLabels": [
                        "Placebo (P)"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Oral glucose tolerance test",
                    "description": "Participants will complete a standard oral glucose tolerance test using 75 g of glucose at baseline and blood glucose will be measured.",
                    "timeFrame": "Baseline"
                },
                {
                    "measure": "Oral glucose tolerance test",
                    "description": "Participants will complete a standard oral glucose tolerance test using 75 g of glucose at 14 weeks and blood glucose will be measured.",
                    "timeFrame": "14 weeks"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Hemoglobin A1C",
                    "description": "Participant hemoglobin A1C will be evaluated at baseline.",
                    "timeFrame": "Baseline"
                },
                {
                    "measure": "Hemoglobin A1C",
                    "description": "Participant hemoglobin A1C will be evaluated at 14 weeks.",
                    "timeFrame": "14 weeks"
                }
            ],
            "otherOutcomes": [
                {
                    "measure": "Fat biopsy",
                    "description": "Beiging of fat as measured in the lab by histochemistry.",
                    "timeFrame": "Baseline"
                },
                {
                    "measure": "Fat biopsy",
                    "description": "Beiging of fat as measured in the lab by histochemistry.",
                    "timeFrame": "14 weeks"
                },
                {
                    "measure": "Muscle biopsy",
                    "description": "Fiber type, as measured in the lab by histochemistry.",
                    "timeFrame": "Baseline"
                },
                {
                    "measure": "Muscle biopsy",
                    "description": "Fiber type, as measured in the lab by histochemistry.",
                    "timeFrame": "14 weeks"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Hemoglobin A1C between 5.7 and 6.4\n* Body mass index between 27 and 45\n\nExclusion Criteria:\n\n* Diabetes\n* Chronic use of any antidiabetic medications\n* Any unstable medical condition\n* Use of steroids or daily use of NSAIDS\n* History of chronic inflammatory conditions\n* Use of anticoagulants\n* Contraindications to the use of mirabegron or tadalafil\n* Any condition deemed risky by the study physician",
            "healthyVolunteers": true,
            "sex": "ALL",
            "minimumAge": "35 Years",
            "maximumAge": "65 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Douglas Long, M.S.",
                    "role": "CONTACT",
                    "phone": "859-323-5438",
                    "email": "delong2@uky.edu"
                },
                {
                    "name": "Philip Kern, M.D.",
                    "role": "CONTACT",
                    "phone": "859-218-1394",
                    "email": "pake222@uky.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Philip Kern, M.D.",
                    "affiliation": "University of Kentucky",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "University of Kentucky",
                    "status": "RECRUITING",
                    "city": "Lexington",
                    "state": "Kentucky",
                    "zip": "40536",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Douglas Long",
                            "role": "CONTACT",
                            "phone": "859-323-5438",
                            "email": "delong2@uky.edu"
                        },
                        {
                            "name": "Philip Kern, M.D.",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.98869,
                        "lon": -84.47772
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000011236",
                    "term": "Prediabetic State"
                }
            ],
            "ancestors": [
                {
                    "id": "D000003920",
                    "term": "Diabetes Mellitus"
                },
                {
                    "id": "D000044882",
                    "term": "Glucose Metabolism Disorders"
                },
                {
                    "id": "D000008659",
                    "term": "Metabolic Diseases"
                },
                {
                    "id": "D000004700",
                    "term": "Endocrine System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M12701",
                    "name": "Obesity",
                    "relevance": "LOW"
                },
                {
                    "id": "M14117",
                    "name": "Prediabetic State",
                    "asFound": "Pre-diabetes",
                    "relevance": "HIGH"
                },
                {
                    "id": "M20295",
                    "name": "Glucose Intolerance",
                    "relevance": "LOW"
                },
                {
                    "id": "M7115",
                    "name": "Diabetes Mellitus",
                    "relevance": "LOW"
                },
                {
                    "id": "M11639",
                    "name": "Metabolic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M25403",
                    "name": "Glucose Metabolism Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M7862",
                    "name": "Endocrine System Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC18",
                    "name": "Nutritional and Metabolic Diseases"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC19",
                    "name": "Gland and Hormone Related Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000068581",
                    "term": "Tadalafil"
                },
                {
                    "id": "C000520025",
                    "term": "Mirabegron"
                }
            ],
            "ancestors": [
                {
                    "id": "D000014665",
                    "term": "Vasodilator Agents"
                },
                {
                    "id": "D000058986",
                    "term": "Phosphodiesterase 5 Inhibitors"
                },
                {
                    "id": "D000010726",
                    "term": "Phosphodiesterase Inhibitors"
                },
                {
                    "id": "D000004791",
                    "term": "Enzyme Inhibitors"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000064804",
                    "term": "Urological Agents"
                },
                {
                    "id": "D000058667",
                    "term": "Adrenergic beta-3 Receptor Agonists"
                },
                {
                    "id": "D000000318",
                    "term": "Adrenergic beta-Agonists"
                },
                {
                    "id": "D000000322",
                    "term": "Adrenergic Agonists"
                },
                {
                    "id": "D000018663",
                    "term": "Adrenergic Agents"
                },
                {
                    "id": "D000018377",
                    "term": "Neurotransmitter Agents"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M279",
                    "name": "Tadalafil",
                    "asFound": "Optimization",
                    "relevance": "HIGH"
                },
                {
                    "id": "M244406",
                    "name": "Mirabegron",
                    "asFound": "Linear",
                    "relevance": "HIGH"
                },
                {
                    "id": "M17412",
                    "name": "Vasodilator Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M29332",
                    "name": "Phosphodiesterase 5 Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M13629",
                    "name": "Phosphodiesterase Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M7951",
                    "name": "Enzyme Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M20746",
                    "name": "Adrenergic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M29193",
                    "name": "Adrenergic beta-3 Receptor Agonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M3670",
                    "name": "Adrenergic beta-Agonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M3673",
                    "name": "Adrenergic Agonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M20504",
                    "name": "Neurotransmitter Agents",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "VaDiAg",
                    "name": "Vasodilator Agents"
                },
                {
                    "abbrev": "Urol",
                    "name": "Urological Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}